Functional Characterization of Novel Mutations Affecting Survivin (BIRC5)-Mediated Therapy Resistance in Head and Neck Cancer Patients

Medizin & Biologie

• Survivin 100%
• Head and Neck Neoplasms 83%
• Mutation 46%
• Nuclear Export Signals 37%
• Squamous Cell Carcinoma of Head and Neck 37%
• Therapeutics 13%
• Laser Capture Microdissection 11%
• Neoplasms 10%
• Heterologous Transplantation 10%
• R Factors 10%
• Biopsy 10%
• Cell Nucleus Active Transport 9%
• Microinjections 9%
• Ectopic Gene Expression 9%
• Nuclear Proteins 8%
• Cisplatin 7%
• Cytoplasm 6%
• Apoptosis 5%
• Drug Therapy 4%